Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous Chimeric Receptor T Cells in HER2+ Advanced Breast Cancer and Other Solid Tumors

NCT06027983 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT06027983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06027983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous Chimeric Receptor T Cells in HER2+ Advanced Breast Cancer and Other Solid Tumors
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2+ advanced breast cancer, other solid tumors